FOLH1 and neoplasm: The FDA-approved lead rhPSMA diagnostic radiopharmaceutical [18F]flotufolastat (18F-rhPSMA-7.3) demonstrated favourable biodistribution and diagnostic efficacy for N-staging and localization of biochemical relapse in patients with recently diagnosed and recurrent PCs.113 In a first validation of the radiohybrid technology for therapeutic applications, [177Lu]Lu-rhPSMA-7.3 demonstrated 2.8-fold and 4.7-fold increases in tumour uptake compared with [177Lu]Lu-PSMA I&T at 1 and 168 h after injection, respectively.